PT1556020E - Utilização de compostos antagonistas de cgrp para o tratamento da psoríase - Google Patents

Utilização de compostos antagonistas de cgrp para o tratamento da psoríase Download PDF

Info

Publication number
PT1556020E
PT1556020E PT03784467T PT03784467T PT1556020E PT 1556020 E PT1556020 E PT 1556020E PT 03784467 T PT03784467 T PT 03784467T PT 03784467 T PT03784467 T PT 03784467T PT 1556020 E PT1556020 E PT 1556020E
Authority
PT
Portugal
Prior art keywords
psoriasis
treatment
antagonist compounds
cgrp antagonist
remedying
Prior art date
Application number
PT03784467T
Other languages
English (en)
Inventor
Birkir Sveinsson
Original Assignee
Birkir Sveinsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Birkir Sveinsson filed Critical Birkir Sveinsson
Publication of PT1556020E publication Critical patent/PT1556020E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5753—Calcitonin gene related peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
PT03784467T 2002-08-12 2003-08-12 Utilização de compostos antagonistas de cgrp para o tratamento da psoríase PT1556020E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IS6496 2002-08-12

Publications (1)

Publication Number Publication Date
PT1556020E true PT1556020E (pt) 2009-05-29

Family

ID=36701412

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03784467T PT1556020E (pt) 2002-08-12 2003-08-12 Utilização de compostos antagonistas de cgrp para o tratamento da psoríase

Country Status (23)

Country Link
US (5) US20110150890A1 (pt)
EP (1) EP1556020B1 (pt)
JP (1) JP2006501216A (pt)
KR (1) KR101070213B1 (pt)
CN (1) CN1674919A (pt)
AT (1) ATE423553T1 (pt)
AU (1) AU2003260944B2 (pt)
BR (1) BR0313388A (pt)
CA (1) CA2495498C (pt)
DE (1) DE60326370D1 (pt)
DK (1) DK1556020T3 (pt)
EA (1) EA008744B1 (pt)
ES (1) ES2323170T3 (pt)
IL (1) IL166761A (pt)
IS (1) IS2902B (pt)
MX (1) MXPA05001649A (pt)
NO (1) NO20051262L (pt)
NZ (1) NZ538615A (pt)
PL (1) PL375536A1 (pt)
PT (1) PT1556020E (pt)
RS (1) RS52750B (pt)
SI (1) SI1556020T1 (pt)
WO (1) WO2004014351A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11517612B2 (en) 2016-11-18 2022-12-06 Nepsone Ehf Methods of treating inflammatory skin disorders
PT1556020E (pt) 2002-08-12 2009-05-29 Birkir Sveinsson Utilização de compostos antagonistas de cgrp para o tratamento da psoríase
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
KR20080068062A (ko) 2005-11-14 2008-07-22 리나트 뉴로사이언스 코퍼레이션 칼시토닌 유전자-관련 펩티드에 대해 지시되는 길항제 항체및 그의 사용 방법
ES2689322T3 (es) 2008-03-04 2018-11-13 Teva Pharmaceuticals International Gmbh Métodos para tratar el dolor crónico
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
RU2535074C2 (ru) 2009-08-28 2014-12-10 Лэйбрис Байолоджикс, Инк. Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
SG194973A1 (en) 2011-05-20 2013-12-30 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
AU2012258976B8 (en) 2011-05-20 2017-07-20 H. Lundbeck A/S Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
US9745373B2 (en) 2011-05-20 2017-08-29 Alderbio Holdings Llc Anti-CGRP compositions and use thereof
JP5923375B2 (ja) * 2012-04-24 2016-05-24 花王株式会社 Ｃｇｒｐ応答性促進剤
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
AU2015230933B2 (en) 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2016044224A1 (en) 2014-09-15 2016-03-24 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
EP3247382B1 (en) 2015-01-22 2020-05-06 Ram, Isanaka Peptide for treating inflammatory diseases
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
EP3313518A1 (en) * 2015-06-29 2018-05-02 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
EP3641746B1 (en) * 2017-06-19 2024-11-20 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
WO2019087161A1 (en) * 2017-11-06 2019-05-09 Auckland Uniservices Limited Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof
BR112020019882A2 (pt) 2018-04-02 2021-01-05 Amgen Inc. Composições de erenumabe e seus usos
US20210386829A1 (en) * 2018-05-04 2021-12-16 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
AU2020206241A1 (en) 2019-01-08 2021-08-26 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
WO2020153520A1 (ko) * 2019-01-25 2020-07-30 (주)아모레퍼시픽 벤조산아마이드 화합물 및 용해보조제를 포함하는 조성물
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
AR126954A1 (es) * 2021-09-02 2023-12-06 Biohaven Pharm Holding Co Ltd Métodos para tratar la psoriasis con uno o más antagonistas de receptores de cgrp

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504457A (ja) * 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド カルシトニンレセプター
FR2729855A1 (fr) * 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2732220B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
EP0737471A3 (fr) 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
JP2002511836A (ja) * 1996-09-09 2002-04-16 スミスクライン・ビーチャム・コーポレイション 化合物および方法
WO1998056779A1 (en) * 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US6214816B1 (en) * 1998-03-17 2001-04-10 Novo Nordisk A/S Heterocyclic compounds
ES2137136B1 (es) * 1998-05-18 2000-07-01 Esteve Labor Dr Empleo de derivados de aril (o heteroaril) azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de la inflamacion neurogenica.
JP2002525371A (ja) * 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
SK9722003A3 (en) 2001-02-01 2004-05-04 Biogen Inc Methods for treating or preventing skin disorders using CD2-binding agents
PT1556020E (pt) 2002-08-12 2009-05-29 Birkir Sveinsson Utilização de compostos antagonistas de cgrp para o tratamento da psoríase
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
WO2009033809A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2018022664A1 (en) 2016-07-26 2018-02-01 Flagship Pioneering, Inc. Neuromodulating compositions and related therapeutic methods for the treatment of inflammatory and autoimmune diseases

Also Published As

Publication number Publication date
BR0313388A (pt) 2005-07-05
WO2004014351A3 (en) 2004-06-17
NZ538615A (en) 2008-03-28
JP2006501216A (ja) 2006-01-12
DK1556020T3 (da) 2009-06-22
DE60326370D1 (de) 2009-04-09
US20230181693A1 (en) 2023-06-15
CA2495498A1 (en) 2004-02-19
EA200500306A1 (ru) 2005-08-25
US11266718B2 (en) 2022-03-08
AU2003260944B2 (en) 2009-05-14
IS2902B (is) 2014-10-15
PL375536A1 (en) 2005-11-28
ATE423553T1 (de) 2009-03-15
US20110150890A1 (en) 2011-06-23
AU2003260944A1 (en) 2004-02-25
ES2323170T3 (es) 2009-07-08
CN1674919A (zh) 2005-09-28
CA2495498C (en) 2014-04-15
MXPA05001649A (es) 2005-05-27
KR101070213B1 (ko) 2011-10-06
EP1556020A2 (en) 2005-07-27
EP1556020B1 (en) 2009-02-25
IS7741A (is) 2005-03-14
US10668132B2 (en) 2020-06-02
WO2004014351A2 (en) 2004-02-19
US20200338168A1 (en) 2020-10-29
US9585940B2 (en) 2017-03-07
SI1556020T1 (sl) 2009-08-31
KR20050056198A (ko) 2005-06-14
EA008744B1 (ru) 2007-08-31
RS20050132A (sr) 2007-11-15
IL166761A0 (en) 2006-01-15
US20140220030A1 (en) 2014-08-07
NO20051262L (no) 2005-03-11
RS52750B (sr) 2013-08-30
IL166761A (en) 2010-12-30
US20170065681A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
IL166761A0 (en) Use of CGRP antagonist compounds for treatment of psoriasis
EP1429729A4 (en) COMBINED METHOD OF FORMING WITH A CHOLESTERIC STRENGTH, A RENIN-ANGIOTENSIN-INHIBITOR AND ACETYL-SALICYLIC ACID
WO2004017896A3 (en) Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
ATE277596T1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
AU2003268144A1 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
CY2439B1 (en) Alpha-TNF antagonists in a cosmetic, pharmaceutical or dermotological composition.
IL178745A0 (en) Methods for treatment and management of scleroderma using 4-(amino)-2(2,6-dioxo(3-piperidyl))-isoindoline -1,3-dione
AU2003301190A8 (en) Administration of capsaicinoids
WO2005011586A3 (en) Treatment and preventi0n of cardiovascular events
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
DK0714304T3 (da) Terapeutisk system til behandling af psoriasis
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
IL167890A (en) Use of a chorionic gonadotropin in the preparation of a medicament for treating a chronic pelvic pain syndrome
BR0307022A (pt) Método de tratamento de um paciente que precisa de analgesia
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
WO1998005354A3 (en) Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors
MX2024008330A (es) Combinacion de obicetrapib e inhibidor de sglt2
WO2005009388A3 (en) Antiglucocorticoids for the treatment of catatonia
Lavrova et al. Modern pharmacotherapy of onychomycosis
WO2007002174A3 (en) A method of treatment of hormone depletion induced vasomotor symptoms
UA36361A (uk) Спосіб лікування захворювань щитовидної залози
BR0013552A (pt) Azatioprina tópica para o tratamento de doenças auto-imunes orais